评估Neushelium ft在治疗静脉腿溃疡治疗的功效
评估静脉腿溃疡愈合的Nepolium ft的疗效:一项随机对照多中心试验
This is a randomized controlled trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating venous leg ulcers.
研究概览
详细说明
This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care alone, or standard of care plus NeoThelium FT. As this is a post-marketing study, it will gather information about how effective the treatment is in treating venous leg ulcers. All subjects will complete two week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 16 weeks. Secondary endpoints consist of wound area reduction rates, time to closure, follow-up closure, and pain assessment.
研究类型
阶段
- 不适用
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or Female, 18 years of age or older
- Subject has a medical diagnosis of Venous Insufficiency with an open wound to the lower extremity
- Subject has a Venous Leg Ulcer present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
- Subject has a Venous Leg Ulcer with a historical wound measurement showing less than 50% healing in 30 days prior to randomization
- Subject has a Venous Leg Ulcer with screening wound measurement showing less than 25% healing in 14 days prior to randomization
- Subject has a Venous Leg Ulcer Wagner 1, 2, and 3 without infection or clinically visible exposed bone
- Index ulcer is a minimum of 1cm2 and a maximum of 40cm2 at first treatment visit
- Venous Leg Ulcer is being treated with compression therapy for 14 days prior to randomization
- Adequate circulation of ulcer demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization
- Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
- Index ulcer is free of necrotic debris prior to NeoThelium FT application
- Female subjects of childbearing potential having a negative pregnancy test prior to randomization
- Subject is able and willing to follow the protocol requirements
- Subject had signed informed consent
- If 2 or more ulcers are present, the ulcers must be separated by at least 1 cm
Exclusion Criteria:
- Subject has a known life expectancy of <1 year
- Subject is unable to comply with protocol treatment
- Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing
- Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
- Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
- Known contraindications to tissue-engineered allograft
- Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
- Wound reduces in area by ≥25% after 14 days of SOC prior to randomization
- Subject is pregnant or breastfeeding
- Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the ulcer surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
- Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
- Venous Leg Ulcer with active infection
- Wound depth with visible exposed bone
- HBOT within 14 days prior to randomization
- Revascularization surgery on the index ulcer leg within 30 days of screening phase
- Index ulcer suspicious of neoplasm in the opinion of the principal investigator
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:No Intervention: Standard of Care
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
|
实验性的:Intervention: NeoThelium FT & Standard of Care
Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading |
NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Complete Wound Closure
大体时间:1-12 weeks
|
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure. |
1-12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Follow-Up Closure
大体时间:2 weeks
|
Number of wounds remaining closed during the 2-week follow-up |
2 weeks
|
|
Percentage Wound Area Change
大体时间:1-12 weeks
|
The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination. |
1-12 weeks
|
|
Pain Assessment
大体时间:Day 0, Day 14, Day 35, Day 56, Day 84
|
Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points |
Day 0, Day 14, Day 35, Day 56, Day 84
|
|
Time to Closure
大体时间:1-12 weeks
|
Average number of grafts and/or weeks used to achieve wound closure |
1-12 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adverse Events and Serious Adverse Events
大体时间:Day -14 through 91 days
|
The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported. |
Day -14 through 91 days
|
|
Wound closure rate in comparison to initial area
大体时间:Day 0 through Day 84
|
Wound healing rate vs wound area categories 0.5-1 cm2, >1-3cm2, >3-5cm2, etc. |
Day 0 through Day 84
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- VELOCITY
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.